查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1830616

前列腺癌治疗市场（按治疗机制、治疗线、配方、分销管道和最终用户）—2025-2032 年全球预测

Prostate Cancer Therapeutics Market by Therapeutic Mechanism, Therapy Line, Formulation, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年前列腺癌治疗市场规模将达到 175.9 亿美元，复合年增长率为 6.50%。

主要市场统计数据
基准年2024年 106.2亿美元
预计2025年 113.2亿美元
预测年份：2032年 175.9亿美元
复合年增长率（%） 6.50%

对不断发展的临床实践、诊断整合和治疗创新的前瞻性概述，这些正在重新定义全球前列腺癌的治疗和管理方式

在分子诊断、新型治疗方法和不断发展的治疗模式的推动下，前列腺癌的治疗正在经历重大变革时期。近年来，临床医生和研发人员已从广泛的细胞毒性疗法转向精准治疗策略，这些策略选择性地靶向肿瘤生物学特性，并利用基因组学和成像技术发现的弱点。同时，放射性药物和标靶治疗的创新正在再形成临床对疾病控制和耐受性的预期，促使临床医生重新考虑分期给药顺序和联合用药策略。

这种动态环境为药物开发商、支付方、医疗保健提供者和患者权益组织带来了新的机会和营运挑战。相关人员越来越重视在治疗路径早期整合诊断检测，以指导个人化治疗方案。同时，临床试验设计也在不断发展，涵盖生物标记富集、自适应框架和分散式要素，以加快入组速度并提高患者代表性。这些转变凸显了肿瘤学家、核医学专家、遗传咨询师和卫生系统之间的跨学科合作日益重要，有助于将创新转化为永续的治疗标准。

诊断突破、放射性药物的应用、标靶药物以及新的商业模式如何重塑前列腺癌的治疗通讯协定和护理可及性

前列腺癌治疗领域正在经历一场变革性的转变，其驱动力在于诊断精准度、新型治疗方法和策略性商业化方法的融合。 PSMA标靶成像和不断扩展的基因组组合等诊断进展，如今为临床医生提供了可操作的数据，用于指导标靶治疗的选择，从而能够更早、更准确地识别PARP抑制剂和放射性配体疗法的候选药物。同时，放射性药物正从利基临床实验药物转变为针对特定患者群体的成熟治疗方案，从而改变临床路径和供应链需求。

随着雄性激素受体路径抑制剂和新一代小分子药物在抗药性机制方面的不断改进，标靶药物的创新正在加速。免疫疗法正在优化患者选择，以提高迄今为止观察到的适度缓解率，而细胞疗法和治疗性疫苗仍然是活跃的研究方向。製造商和医疗保健提供者正在合作进行专业分销、低温运输物流和患者援助项目，以确保患者能够及时获得需要特殊处理的治疗药物。这些累积的变化正在推动医疗保健系统重新思考治疗流程和报销策略，以适应高成本、更高价值的干预措施。

2025年进口药品投入品和专用放射性药物材料的关税政策变化对营运、供应链和取得的影响

影响关税和跨境贸易的政策变化可能会对依赖专业化投入和物流的疗法产生集中的下游影响。进口活性药物原料药、前驱化学品和放射性化学品的关税上调，可能会增加製造商以及受託製造厂商的生产成本，进而影响定价策略、库存缓衝和供应协议。鑑于放射性药物生产和分销的技术复杂性和监管限制，即使关税制度的微小变化也可能使采购决策复杂化，并迫使企业进行短期营运调整。

为了应对关税带来的成本压力，相关人员已开始评估降低风险的策略。这些措施包括实现供应商组合多样化、重新谈判长期采购合约、加速近岸外包和区域製造伙伴关係，以及增加对国内放射性配体合成能力的投资。此外，卫生系统和付款人可能会加强对比较有效性和现实世界结果的审查，以证明高成本治疗方法的报销是合理的。在临床方面，製造商必须与物流供应商更紧密地合作，以确保可预测的时间敏感疗法的供应，临床试验赞助者可能需要建立更大的用于多中心临床试验的在临床实验药物安全库存。总而言之，这些营运和策略转变将决定关税变化如何影响新疗法的可及性、可负担性以及患者获得新疗法的速度。

特定细分领域的影响塑造了治疗机制、治疗线、配方、分销管道和最终用户动态的临床价值提案和产业计画

详细的细分视图阐明了临床机会和商业性复杂性的交会点。根据治疗机制，市场分为化疗、荷尔蒙疗法、免疫治疗、放射性药物和标靶治疗。化疗包括铂化合物和紫杉烷类。荷尔蒙疗法细分为抗雄性激素、CYP17 抑制剂、GnRH促效剂和 GnRH 拮抗剂。免疫疗法分为癌症疫苗、细胞疗法和查核点抑制剂。放射性药物分为 α 放射体和 β 放射体。标靶治疗分为单株抗体、PAR 抑制剂和蛋白酪氨酸激酶抑制剂。根据治疗线，治疗途径分为一线、二线和三线或以上。根据剂型，市场分为注射剂和口服药物。根据销售管道，管道包括医院药房、网路药房和零售药房。根据最终用户，分析涵盖癌症中心、居家照护提供者、医院和专科诊所。

从策略角度来看，治疗机制细分揭示了研发投资将带来最大差异化的领域。目前，放射性药物和标靶药物为个人化治疗提供了最有力的途径，而细胞毒性化学疗法在某些临床场景中仍发挥作用。治疗线细分錶明需要价值提案和证据生成，因为仿製药的核准通常依赖生物标记定义的人群。剂型细分推动商业规划，因为口服药物优先考虑依从性计划和患者支持基础设施，而注射剂和放射性标记产品则需要专门的给药地点和低温运输物流。分销管道和最终用户细分凸显了根据供应商能力、报销环境和患者偏好定制分销策略的必要性，以最大限度地提高及时性并优化护理途径。

透过对美洲、欧洲、中东和非洲以及亚太地区的采用、基础设施准备和报销细节进行比较分析，确定治疗方法所获得的轨迹

区域动态显着影响前列腺癌治疗的采用、报销和发展重点。在美洲，临床创新和商业性发布能力仍然高度集中，这得益于既定的监管途径和先进诊断技术的广泛采用。这种环境促进了放射性配体疗法和生物标记主导的标靶药物的快速商业化，同时也产生了需要强有力的真实世界证据来支持持续可及性的付款人审查。相较之下，欧洲、中东和非洲在定价政策、报销计画和医疗保健基础设施方面表现出差异性。一些欧洲市场正在其国家医疗保健系统中迅速采用新的诊断方法和高成本治疗方法，而其他市场则在逐步取得进展。一些中东和北非国家正在选择性地投资核子医学和专门的肿瘤中心，作为更广泛的医疗保健系统加强工作的一部分。

亚太地区临床试验活动快速发展，生产能力不断提升，报销成熟度也参差不齐。该地区多个国家正在成为重要的临床开发中心，为生物标记主导的研究提供大量患者群体，并不断提升核医学能力以支持放射性药物计画。然而，获取途径仍然不均衡，价格压力和区域指南调整正在影响药物的吸收。跨地区临床试验的跨境合作、诊断标准的协调以及对时间敏感型治疗的物流投资是通用的战略重点，这些将决定药物的采用速度以及在不久的将来受益最大的患者群体。

深入了解公司在前列腺癌治疗领域塑造竞争地位和商业准备的策略重点、伙伴关係框架和能力投资

前列腺癌治疗领域的企业策略体现了其对标靶治疗、策略伙伴关係和真实世界证据产生的深度投资。现有製药公司正将资源集中于PARP抑制剂、下一代雄激素受体拮抗剂，并推进已通过核准药物的生命週期管理，同时与核子医学专家和契约製造合作，将放射性配体疗法商业化。规模较小的生物技术和专科公司则专注于生物标记驱动的适应症，并寻求细胞疗法和治疗性疫苗等利基疗法，以加速临床开发并最大限度地实现差异化。

纵观竞争格局，那些展现出综合实力（例如诊断伙伴关係、注射剂和放射性药物分销网络以及强大的患者支持计划）的公司，在商业化准备方面正获得显着优势。策略性併购和授权交易正在重塑投资组合，使大型公司能够将专业技术引入内部，而中型市场公司则能够利用合作伙伴的商业化管道。此外，投资于数位互动工具、分散临床临床实验营运和长期真实世界结果研究的公司，正在定位自己，以便更快地响应付款方的需求和临床医生的偏好。这些企业行动正在加速将新科学转化为可及的治疗方法，同时重塑合作伙伴生态系统。

为商业、临床和供应链领导者提供实用且以证据为中心的策略，以加速采用、保护获取途径并减轻治疗开发中的政策主导风险

产业领导者应优先考虑将科学差异化与营运准备结合的合作策略。首先，将诊断技术许可引入途径整合到临床开发项目中，以确保在产品上市前建立伴随检测和患者识别能力。与诊断技术提供者和付款方的早期合作可以简化许可引入和报销谈判。其次，透过多元化供应商、就关键投入品进行多年期合约谈判以及扩大区域製造伙伴关係来增强供应链的弹性，以降低关税和物流风险。第三，投资于证据生成，不仅包括关键临床试验，还包括註册登记和实用研究，以捕捉现实世界的疗效、安全性和健康经济成果，从而支持报销并增强处方医生的信心。

除了这些核心行动之外，企业还应重新评估分销策略，以应对居家医疗和专科诊所在註射剂和放射性药物方面日益增长的作用，并设计患者援助项目，以提高口服药物的依从性，并促进患者及时获得复杂疗法。企业也应深化与关键高阶主管的跨部门合作，并与付款方进行对话，共同製定反映长期临床效益的价值框架。最后，企业应采用灵活的商业模式，包括在适当情况下采用风险分担安排和基于结果的合同，并保持情景规划能力，以快速应对政策变化、资费调整和不断发展的临床指南。

透过整合二手证据、临床试验和监管审查、专家访谈和情境检验的严格、多方法研究途径获得可行的见解

调查方法结合了系统性的二手资料研究、专家的初步调查和多源数据三角测量，从而全面观点治疗、监管和商业动态。二手资料研究涵盖了同行评审文献、临床试验註册库、监管公告和公司出版物中的治疗机制、近期核准和研发管线活动。初步资料研究包括与肿瘤学、核子医学领域的关键意见领袖、供应链专业人士、付款方和临床营运专家进行结构化访谈，以检验趋势、支持临床决策模式并强调与专科产品分销和管理相关的营运挑战。

透过对多个资料输入进行交叉验证，并结合情境分析，检验政策和供应中断的影响，增强了分析的严谨性。调查方法强调对临床试验证据和监管轨迹进行定性检验和情境解读，而非定量预测，并结合相关人员研讨会，确保最终建议符合现实的营运约束和策略要求。这种多层次的方法为商业、临床开发和供应链职能部门的决策者提供了可靠且可操作的洞察。

临床创新、营运要务和合作重点的策略整合，以建立永续取得和改善患者治疗效果的途径

前列腺癌治疗格局的演变既带来了巨大的机会，也带来了营运的复杂性。标靶药物、放射性药物和诊断精准度的进步，正在推动临床模式转向更个人化的策略转变，而分销、生产和报销体系必须适应需要专业处理和证据来证明长期价值的疗法。那些将科学创新与切合实际的产业计画相结合的组织——那些能够增强供应弹性、发展诊断和分销伙伴关係并投资于现实世界结果研究的组织——将最有能力将突破性进展转化为永续的患者可及性。

展望未来，产业、临床和政策相关人员之间的合作对于平衡快速治疗创新与公平可及性和成本效益至关重要。透过预测付款人预期、监管要求和当地基础设施限制的变化，相关人员可以主动设计既能带来临床效益又能确保营运可行性的开发和商业化方案。今天的策略选择将决定哪些治疗方法能够有效地惠及患者，以及哪些方法将成为下一代前列腺癌治疗的标准。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • BRCA 突变转移性去势抗性摄护腺癌患者越来越多地采用 PARP 抑制剂
  • 加速将PSMA标靶放射配体疗法整合到晚期摄护腺癌的二线治疗通讯协定中
  • 下一代雄性激素受体降解药物在激素敏感性前列腺癌的早期临床试验中显示出良好的结果
  • 整合以液态生物检体为基础的基因组分析，以个人化前列腺癌治疗途径中的治疗决策
  • 开发针对 PSMA 和 CD3 的双特异性抗体疗法，以促进 T 细胞介导的前列腺肿瘤根除
  • 新兴的联合治疗策略将新型免疫疗法药物与现有的前列腺癌荷尔蒙疗法结合
  • PSMA PET放射性药物的进展使得前列腺癌的早期检测和即时监测成为可能
  • 扩大人工智慧预测分析的应用，以优化前列腺癌的患者分层和治疗方法方案

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章前列腺癌治疗市场（依治疗机制）

  • 化疗
    • 含铂类药物
    • 紫杉烷类
  • 荷尔蒙疗法
    • 抗雄激素
    • CYP17抑制剂
    • GnRH促效剂
    • GnRH拮抗剂
  • 免疫疗法
    • 癌症疫苗
    • 细胞疗法
    • 查核点抑制剂
  • 放射性药物
    • α发射体
    • β射线发射器
  • 标靶治疗
    • 单株抗体
    • PARP抑制剂
    • 蛋白酪氨酸激酶抑制剂

第九章前列腺癌治疗市场（依治疗线）

  • 初级治疗
  • 二级处理
  • 三线治疗及后续治疗

第 10 章前列腺癌治疗市场（按剂型）

  • 注射
  • 口服

第 11 章前列腺癌治疗市场（依通路）

  • 医院药房
  • 网路药局
  • 零售药局

第 12 章前列腺癌治疗市场（按最终用户）

  • 癌症中心
  • 居家照护提供者
  • 医院
  • 专科诊所

第十三章前列腺癌治疗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章前列腺癌治疗市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章前列腺癌治疗市场（按国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Astellas Pharma Inc.
    • Pfizer Inc.
    • Johnson & Johnson
    • F. Hoffmann-La Roche AG
    • Novartis AG
    • Bayer AG
    • AstraZeneca PLC
    • Sanofi SA
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
Product Code: MRR-4342CA3266BF

The Prostate Cancer Therapeutics Market is projected to grow by USD 17.59 billion at a CAGR of 6.50% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.62 billion
Estimated Year [2025] USD 11.32 billion
Forecast Year [2032] USD 17.59 billion
CAGR (%) 6.50%

A forward-looking overview of evolving clinical practice, diagnostic integration, and therapeutic innovation that are redefining how prostate cancer is treated and managed globally

Prostate cancer therapeutics are undergoing a period of meaningful transformation driven by advances in molecular diagnostics, novel therapeutic modalities, and evolving care delivery models. Over the last several years, clinicians and developers have shifted from broad cytotoxic approaches toward precision strategies that selectively target tumor biology and exploit vulnerabilities identified through genomic and imaging technologies. In parallel, innovations in radiopharmaceuticals and targeted therapies are reshaping clinical expectations for disease control and tolerability, prompting clinicians to rethink sequencing and combination strategies for different stages of disease.

This dynamic environment has created new opportunities and operational challenges for pharmaceutical developers, payers, providers, and patient support organizations. Stakeholders increasingly prioritize integration of diagnostic testing early in the care pathway to guide personalized regimens. Meanwhile, clinical trial design is adapting to include biomarker-enrichment, adaptive frameworks, and decentralized elements to accelerate enrollment and broaden patient representation. These shifts underscore the growing importance of multi-disciplinary collaboration among oncologists, nuclear medicine specialists, genetic counselors, and health systems to translate innovation into sustainable standards of care.

How diagnostic breakthroughs, radiopharmaceutical adoption, targeted agents, and new commercial models are collectively reshaping prostate cancer treatment protocols and access

The prostate cancer therapeutic landscape is experiencing transformative shifts driven by convergence of diagnostic precision, novel modalities, and strategic commercialization approaches. Diagnostic advances such as PSMA-targeted imaging and expanded genomic panels now provide clinicians with actionable data that inform targeted therapy selection, enabling earlier and more accurate identification of candidates for PARP inhibitors and radioligand therapies. Concurrently, radiopharmaceuticals have moved from niche investigational status to established therapeutic options for selected patient populations, altering both clinical pathways and supply chain requirements.

Innovation in targeted agents continues apace with incremental improvements in androgen receptor pathway inhibitors and next-generation small molecules that address resistance mechanisms. Immunotherapy efforts are refining patient selection to improve the modest response rates observed to date, while cell-based approaches and therapeutic vaccines persist as active research avenues. Commercial models are adapting to these scientific changes: manufacturers and providers are collaborating on specialized distribution, cold-chain logistics, and patient support programs to ensure timely access for therapies that require unique handling. These cumulative changes are propelling health systems to revise treatment algorithms and reimbursement strategies to accommodate higher-cost, higher-value interventions.

Operational, supply chain, and access implications of tariff policy changes on imported pharmaceutical inputs and specialized radiopharmaceutical materials through 2025

Policy shifts affecting tariffs and cross-border trade can have concentrated downstream effects on therapeutics that rely on specialized inputs and logistics. Increased tariffs on imported active pharmaceutical ingredients, precursor chemicals, or radiochemistry materials can raise production costs for manufacturers and contract development and manufacturing organizations, which in turn may influence pricing strategy, inventory buffers, and supply agreements. Given the technical complexity and regulatory constraints surrounding radiopharmaceutical production and distribution, even modest changes in tariff regimes can complicate sourcing decisions and necessitate near-term operational adjustments.

In response to tariff-driven cost pressures, stakeholders are already evaluating strategies to mitigate exposure. These measures include diversifying supplier portfolios, renegotiating long-term procurement contracts, accelerating nearshoring or regional manufacturing partnerships, and increasing investment in domestic capacity for radioligand synthesis. Additionally, health systems and payers may intensify scrutiny of comparative effectiveness and real-world outcomes to justify reimbursement for higher-cost therapies. Clinically, manufacturers must collaborate more closely with logistics providers to ensure predictable supply for time-sensitive therapies, and sponsors may need to build larger safety stocks for investigational agents used in multicenter trials. Collectively, these operational and strategic shifts will determine how tariff changes influence access, affordability, and the pace at which new therapies reach patients.

Segment-specific implications across therapeutic mechanism, therapy line, formulation, distribution channel, and end-user dynamics that shape clinical value propositions and operational planning

A granular view of segmentation clarifies where clinical opportunity and commercial complexity intersect. Based on therapeutic mechanism, the landscape spans Chemotherapy, Hormone Therapy, Immunotherapy, Radiopharmaceuticals, and Targeted Therapy; the Chemotherapy category further includes Platinum Compounds and Taxanes; the Hormone Therapy category is subdivided into Antiandrogens, CYP17 Inhibitors, GnRH Agonists, and GnRH Antagonists; Immunotherapy is examined through Cancer Vaccines, Cell Therapy, and Checkpoint Inhibitors; Radiopharmaceuticals are analyzed as Alpha Emitters and Beta Emitters; and Targeted Therapy encompasses Monoclonal Antibodies, Parp Inhibitors, and Tyrosine Kinase Inhibitors. Based on therapy line, therapeutic pathways are differentiated into First Line, Second Line, and Third Line and Beyond. Based on formulation, modalities are classified as Injectable and Oral. Based on distribution channel, channels include Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. Based on end user, the analysis considers Cancer Centers, Homecare Providers, Hospitals, and Specialty Clinics.

From a strategic standpoint, therapeutic mechanism segmentation highlights where R&D investment yields the greatest differentiation; radiopharmaceuticals and targeted agents currently offer the strongest pathway to personalized outcomes, while cytotoxic chemotherapy continues to play a role in specific clinical scenarios. Therapy line segmentation informs value proposition and evidence generation needs, with later-line approvals frequently relying on biomarker-defined populations. Formulation segmentation drives commercial planning, since oral agents prioritize adherence initiatives and patient support infrastructure, whereas injectable or radiolabeled products necessitate specialized administration sites and cold-chain logistics. Distribution channel and end-user segmentation underscore the operational necessity of aligning distribution strategies with site capabilities, reimbursement environments, and patient preferences to maximize timely access and optimize care pathways.

Comparative analysis of regional adoption, infrastructure readiness, and reimbursement nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine therapeutic access trajectories

Regional dynamics materially influence adoption, reimbursement, and development priorities for prostate cancer therapeutics. In the Americas, clinical innovation and commercial launch capacity remain highly concentrated, supported by well-established regulatory pathways and broad adoption of advanced diagnostics; this environment incentivizes rapid commercialization of radioligand therapies and biomarker-driven targeted agents, while also generating payer scrutiny that requires robust real-world evidence to support durable access. In contrast, Europe, Middle East & Africa exhibits heterogeneity in pricing policies, reimbursement timelines, and healthcare infrastructure; some European markets adopt new diagnostics and high-cost therapies rapidly under national health systems while others progress incrementally, and countries across the Middle East and Africa are selectively investing in nuclear medicine and specialty oncology centers as part of broader health system strengthening efforts.

Asia-Pacific represents a mix of rapid clinical trial activity, expanding manufacturing capacity, and variable reimbursement maturity. Several countries in the region are emerging as important clinical development hubs, offering large patient populations for biomarker-driven studies and growing nuclear medicine capabilities to support radiopharmaceutical programmes. However, access remains uneven, with pricing pressure and local guideline adaptation influencing uptake. Across all regions, cross-border collaboration on clinical trials, harmonization of diagnostic standards, and investment in logistics for time-sensitive therapies are common strategic priorities that will determine the pace of adoption and the patient populations that will benefit most in the near term.

Insights into corporate strategic priorities, partnership frameworks, and capability investments that determine competitive positioning and commercialization readiness in prostate cancer therapeutics

Corporate strategies in prostate cancer therapeutics reflect deep investments in targeted modalities, strategic partnerships, and real-world evidence generation. Established pharmaceutical firms have concentrated resources on advancing PARP inhibitors, next-generation androgen receptor antagonists, and lifecycle management of approved assets, while also entering collaborations with nuclear medicine specialists and contract manufacturers to commercialize radioligand therapies. Smaller biotech and specialty companies are advancing niche approaches such as cell therapies and therapeutic vaccines, focusing on biomarker-enriched indications to expedite clinical development and maximize differentiation.

Across the competitive landscape, companies that demonstrate integrated capabilities-combining diagnostic partnerships, distribution networks for injectable and radiopharmaceutical products, and robust patient support programs-achieve a clear advantage in commercialization readiness. Strategic M&A and licensing deals continue to realign portfolios, enabling larger players to internalize specialized technologies and enabling mid-sized companies to leverage partners' commercialization channels. Additionally, firms investing in digital engagement tools, decentralized trial operations, and long-term real-world outcomes research position themselves to respond to payer demands and clinician preferences more rapidly. Collectively, these corporate actions are accelerating the translation of novel science into accessible treatment options while reshaping partner ecosystems.

Practical, evidence-focused strategies for commercial, clinical, and supply chain leaders to accelerate adoption, protect access, and mitigate policy-driven risks in therapeutic development

Industry leaders should prioritize coordinated strategies that align scientific differentiation with operational readiness. First, integrate diagnostic adoption pathways into clinical development programs to ensure companion tests and patient identification capabilities are established ahead of launch; early collaboration with diagnostic providers and payers will streamline uptake and reimbursement discussions. Second, strengthen supply chain resiliency by diversifying suppliers, negotiating multi-year agreements for critical inputs, and expanding regional manufacturing partnerships to mitigate tariff and logistics risks. Third, invest in evidence generation that extends beyond pivotal trials to include registries and pragmatic studies capturing real-world effectiveness, safety, and health economic outcomes to support reimbursement and prescriber confidence.

Beyond these core actions, organizations should re-evaluate distribution strategies to accommodate the growing role of homecare and specialty clinics for injectable and radiopharmaceutical products, while designing patient support programs that improve adherence for oral agents and facilitate timely access for complex therapies. Firms must also cultivate cross-disciplinary KOL engagement and payer dialogues to co-develop value frameworks that reflect long-term clinical benefit. Lastly, embrace flexible commercial models including risk-sharing arrangements and outcomes-based contracting where appropriate, and maintain scenario planning capabilities to respond rapidly to policy shifts, tariff adjustments, and evolving clinical guidelines.

A rigorous multi-method research approach integrating secondary evidence, clinical trial and regulatory review, expert interviews, and scenario validation to produce actionable insights

The research approach combined systematic secondary research, primary expert engagement, and multi-source data triangulation to assemble a comprehensive perspective on therapeutic, regulatory, and commercial dynamics. Secondary research drew on peer-reviewed literature, clinical trial registries, regulatory announcements, and company publications to map therapeutic mechanisms, recent approvals, and pipeline activity. Primary research consisted of structured interviews with key opinion leaders in oncology, nuclear medicine, supply chain professionals, payers, and clinical operations experts to validate trends, corroborate clinical decision-making patterns, and surface operational challenges tied to distribution and administration of specialized products.

Analytical rigor was reinforced through cross-validation of findings across multiple data inputs and scenario analysis to test susceptibility to policy and supply disruptions. The methodology emphasized qualitative synthesis and contextual interpretation of clinical trial evidence and regulatory trajectories rather than quantitative projections, and it incorporated stakeholder workshops to ensure the final recommendations align with practical operational constraints and strategic imperatives. This layered approach supports robust, actionable insight for decision-makers across commercial, clinical development, and supply chain functions.

A strategic synthesis of clinical innovation, operational imperatives, and collaborative priorities that frames the pathway to sustainable access and improved patient outcomes

The evolving prostate cancer therapeutics landscape presents both profound opportunity and operational complexity. Advances in targeted agents, radiopharmaceuticals, and diagnostic precision are shifting clinical paradigms toward more personalized strategies, while distribution, manufacturing, and reimbursement systems must adapt to accommodate therapies that require specialized handling and evidence to demonstrate long-term value. Organizations that align scientific innovation with pragmatic operational planning-strengthening supply resilience, forging diagnostic and distribution partnerships, and investing in real-world outcomes research-will be best positioned to translate breakthroughs into sustainable patient access.

Looking ahead, collaboration across industry, clinical, and policy stakeholders will be essential to reconcile rapid therapeutic innovation with equitable access and cost-effectiveness. By anticipating shifts in payer expectations, regulatory requirements, and regional infrastructure constraints, stakeholders can proactively design development and commercialization programs that deliver clinical benefit while safeguarding operational viability. The strategic choices made today will determine which therapies reach patients efficiently and which approaches set the standard for next-generation prostate cancer care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of PARP inhibitors for metastatic castration-resistant prostate cancer in patients with BRCA mutations
  • 5.2. Accelerating integration of PSMA-targeted radioligand therapy into second-line treatment protocols for advanced prostate cancer
  • 5.3. Expansion of next-generation androgen receptor degraders showing promising outcomes in early hormone-sensitive prostate cancer trials
  • 5.4. Integration of liquid biopsy-based genomic profiling to personalize treatment decisions in prostate cancer care pathways
  • 5.5. Development of bispecific antibody therapies targeting PSMA and CD3 to enhance T-cell mediated prostate tumor eradication
  • 5.6. Emergence of combination strategies pairing novel immunotherapy agents with existing hormonal therapies in prostate cancer
  • 5.7. Advances in PSMA PET radiopharmaceuticals enabling earlier detection and real-time monitoring of prostate cancer progression
  • 5.8. Growing utilization of artificial intelligence predictive analytics to optimize patient stratification and therapeutic selection in prostate cancer

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Prostate Cancer Therapeutics Market, by Therapeutic Mechanism

  • 8.1. Chemotherapy
    • 8.1.1. Platinum Compounds
    • 8.1.2. Taxanes
  • 8.2. Hormone Therapy
    • 8.2.1. Antiandrogens
    • 8.2.2. CYP17 Inhibitors
    • 8.2.3. GnRH Agonists
    • 8.2.4. GnRH Antagonists
  • 8.3. Immunotherapy
    • 8.3.1. Cancer Vaccines
    • 8.3.2. Cell Therapy
    • 8.3.3. Checkpoint Inhibitors
  • 8.4. Radiopharmaceuticals
    • 8.4.1. Alpha Emitters
    • 8.4.2. Beta Emitters
  • 8.5. Targeted Therapy
    • 8.5.1. Monoclonal Antibodies
    • 8.5.2. Parp Inhibitors
    • 8.5.3. Tyrosine Kinase Inhibitors

9. Prostate Cancer Therapeutics Market, by Therapy Line

  • 9.1. First Line
  • 9.2. Second Line
  • 9.3. Third Line And Beyond

10. Prostate Cancer Therapeutics Market, by Formulation

  • 10.1. Injectable
  • 10.2. Oral

11. Prostate Cancer Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Prostate Cancer Therapeutics Market, by End User

  • 12.1. Cancer Centers
  • 12.2. Homecare Providers
  • 12.3. Hospitals
  • 12.4. Specialty Clinics

13. Prostate Cancer Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Prostate Cancer Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Prostate Cancer Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Astellas Pharma Inc.
    • 16.3.2. Pfizer Inc.
    • 16.3.3. Johnson & Johnson
    • 16.3.4. F. Hoffmann-La Roche AG
    • 16.3.5. Novartis AG
    • 16.3.6. Bayer AG
    • 16.3.7. AstraZeneca PLC
    • 16.3.8. Sanofi S.A.
    • 16.3.9. Bristol-Myers Squibb Company
    • 16.3.10. Merck & Co., Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. PROSTATE CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. PROSTATE CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PROSTATE CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)

TABLE 2